Marcin Mikołaj Grzybowski

Dr. Marcin Mikołaj Grzybowski

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2014 in Parasitology
Verified
Journal Article
Closed access
EHEla Hiszczynska-Sawicka
Ela Hiszczynska-Sawicka
JGJustyna Gatkowska
Justyna Gatkowska
MGMarcin Mikołaj Grzybowski
Marcin Mikołaj Grzybowski
HDHenryka Długońska
Henryka Długońska
SUMMARY: Toxoplasma gondiiis a cosmopolitan protozoan parasite that infects a wide range of mammal and bird species. Common infection leads to high economic (e.g. abortions in sheep) and human (e.g. congenital toxoplasmosis or neurotoxoplasmosis in humans) losses. With one exception (Toxovax™ for sheep), there are no vaccines to prevent human or animal toxoplasmosis. The paper presents the current state and challenges in the development of a vaccine against toxoplasmosis, designed for farm animals either bred for consumption or commonly kept on farms and involved in parasite transmission. So far, the trials have mostly revolved around conventional vaccines and, compared with the research using laboratory animals (mainly mice), they have not been very numerous. However, the results obtained are promising and could be a good starting point for developing an effective vaccine to prevent toxoplasmosis.

1 January 2011 in Vaccine
Verified
Journal Article
Closed access
BDBożena R. Dziadek
Bożena R. Dziadek
JGJustyna Gatkowska
Justyna Gatkowska
ABAnna Brzostek
Anna Brzostek
JDJaroslaw Dziadek
Jaroslaw Dziadek
KDKatarzyna Dzitko
Katarzyna Dzitko
HDHenryka Dlugonska
Henryka Dlugonska

17 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MGMarcin Mikołaj Grzybowski
Marcin Mikołaj Grzybowski
PSPaulina Seweryna Stańczak
Paulina Seweryna Stańczak
PPPaulina Pomper
Paulina Pomper
RBRoman Blaszczyk
Roman Blaszczyk
BBBartłomiej Borek
Bartłomiej Borek
ZZZbigniew Zaslona
Zbigniew Zaslona
Background: Arginases play essential roles in metabolic pathways, determining the fitness of both immune and tumour cells. Along with the previously validated role of ARG1 in cancer, the particular significance of ARG2 as a therapeutic target has emerged as its levels correlate with malignant phenotype and poor prognosis. These observations unveil arginases, and specifically ARG2, as well-validated and promising therapeutic targets. OATD-02, a new boronic acid derivative, is the only dual inhibitor, which can address the benefits of pharmacological inhibition of arginase 1 and 2 in cancer. Methods: The inhibitory activity of OATD-02 was determined using recombinant ARG1 and ARG2, as well as in a cellular system using primary hepatocytes and macrophages. In vivo antitumor activity was determined in syngeneic models of colorectal and kidney carcinomas (CT26 and Renca, respectively), as well as in an ARG2-dependent xenograft model of leukaemia (K562). Results: OATD-02 was shown to be a potent dual (ARG1/ARG2) arginase inhibitor with a cellular activity necessary for targeting ARG2. Compared to a reference inhibitor with predominant extracellular activity towards ARG1, we have shown improved and statistically significant antitumor efficacy in the CT26 model and an immunomodulatory effect reflected by Treg inhibition in the Renca model. Importantly, OATD-02 had a superior activity when combined with other immunotherapeutics. Finally, OATD-02 effectively inhibited the proliferation of human K562 leukemic cells both in vitro and in vivo. Conclusions: OATD-02 is a potent small-molecule arginase inhibitor with optimal drug-like properties, including PK/PD profile. Excellent activity against intracellular ARG2 significantly distinguishes OATD-02 from other arginase inhibitors. OATD-02 represents a very promising drug candidate for the combined treatment of tumours, and is the only pharmacological tool that can effectively address the benefits of ARG1/ARG2 inhibition. OATD-02 will enter clinical trials in cancer patients in 2022.

17 March 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
BBBartlomiej Borek
Bartlomiej Borek
JNJulita Nowicka
Julita Nowicka
AGAnna Gzik
Anna Gzik
MDMarek Dziegielewski
Marek Dziegielewski
KJKarol Jedrzejczak
Karol Jedrzejczak
RBRoman Blaszczyk
Roman Blaszczyk
Pharmacologic inhibition of the controlling immunity pathway enzymes arginases 1 and 2 (ARG1 and ARG2) is a promising strategy for cancer immunotherapy. Here, we report the discovery and development of OATD-02, an orally bioavailable, potent arginases inhibitor. The unique pharmacologic properties of OATD-02 are evidenced by targeting intracellular ARG1 and ARG2, as well as long drug-target residence time, moderate to high volume of distribution, and low clearance, which may jointly provide a weapon against arginase-related tumor immunosuppression and ARG2-dependent tumor cell growth. OATD-02 monotherapy had an antitumor effect in multiple tumor models and enhanced an efficacy of the other immunomodulators. Completed nonclinical studies and human pharmacokinetic predictions indicate a feasible therapeutic window and allow for proposing a dose range for the first-in-human clinical study in patients with cancer. Significance: We have developed an orally available, small-molecule intracellular arginase 1 and 2 inhibitor as a potential enhancer in cancer immunotherapy. Because of its favorable pharmacologic properties shown in nonclinical studies, OATD-02 abolishes tumor immunosuppression induced by both arginases, making it a promising drug candidate entering clinical trials.

1 May 2012 in Experimental Parasitology
Verified
Journal Article
Closed access
BDBożena R. Dziadek
Bożena R. Dziadek
JGJustyna Gatkowska
Justyna Gatkowska
MGMarcin Mikołaj Grzybowski
Marcin Mikołaj Grzybowski
JDJaroslaw Dziadek
Jaroslaw Dziadek
KDKatarzyna Dzitko
Katarzyna Dzitko
HDHenryka Dlugonska
Henryka Dlugonska

28 May 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MGMarcin Mikołaj Grzybowski
Marcin Mikołaj Grzybowski
YUYasemin Uçal
Yasemin Uçal
AMAngelika Muchowicz
Angelika Muchowicz
TRTomasz Rejczak
Tomasz Rejczak
AKAgnieszka Kikulska
Agnieszka Kikulska
ZZZbigniew Zasłona
Zbigniew Zasłona
Metabolic reprogramming within the tumor microenvironment (TME) plays a central role in cancer progression and immune evasion, with L-arginine metabolism emerging as a key regulatory axis. Arginase overexpression depletes intratumoral L-arginine, thus suppressing T-cell proliferation while fuelling tumor growth through polyamine biosynthesis. OATD-02, a novel dual arginase (ARG1/ARG2) inhibitor, reprograms tumor metabolism by restoring L-arginine availability and reducing the levels of polyamines, thereby shifting the TME toward a more immunostimulatory state. Unlike ARG1-selective inhibitors with limited intracellular uptake, OATD-02 effectively inhibits both extracellular and intracellular arginases, thereby addressing a major limitation of first-generation arginase inhibitors. To visualize the pharmacodynamic effects of OATD-02 dosing in mice with spatial resolution, we employed MALDI mass spectrometry imaging (MALDI-MSI), thus enabling direct mapping of metabolic changes within tumor tissues. In preclinical models, OATD-02 treatment led to widespread accumulation of intratumoral L-arginine with concomitant depletion of polyamines and resulted in metabolic shifts that correlated with increased immune cell infiltration and an improved response to immune checkpoint blockade. These findings underscore the role of dual arginase inhibition in reshaping tumor metabolism and overcoming immune suppression by restoring the metabolic fitness of immune cells to fight cancer. The metabolic changes caused by OATD-02 treatment resulted in significantly enhanced antitumor immune responses, increased T-cell infiltration in tumors, expansion of CD8⁺ T cells in draining lymph nodes, and systemic upregulation of T-cell activation markers. These effects translated into a substantial survival benefit in the CT26 tumor model, particularly when combined with anti-PD-1 therapy, where OATD-02 improved checkpoint blockade efficacy by relieving metabolic constraints affecting tumor-infiltrating lymphocytes. By leveraging the unique capabilities of MALDI-MSI, this study provides high-resolution metabolic insights into the mechanism of action of OATD-02, reinforcing its potential as a next-generation metabolic-immunotherapeutic agent. The observed metabolic reprogramming, coupled with enhanced immune activation and prolonged survival, supports the clinical development of OATD-02 as a promising strategy for enhancing cancer immunotherapy efficacy. OATD-02 is currently undergoing clinical evaluation in a phase I/II trial (NCT05759923), which will further elucidate its safety and therapeutic impact. These findings highlight the potential of arginase-targeted therapies in cancer treatment and underscore the value of MALDI-MSI as a powerful tool for tracking metabolic responses to therapy.